|By PR Newswire||
|August 22, 2014 07:36 AM EDT||
PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con®. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the treatment of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. Mylan has begun shipping this product.
Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), had U.S. sales of approximately $135.05 million for the 12 months ending June 30, 2014, according to IMS Health.
Currently, Mylan has 294 ANDAs pending FDA approval representing $105.7 billion in annual brand sales, according to IMS Health. Forty-three of these pending ANDAs are potential first-to-file opportunities, representing $25.0 billion in annual brand sales, for the 12 months ending Dec. 31, 2013, according to IMS Health.
Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,300 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com
SOURCE Mylan Inc.
Dec. 2, 2016 02:15 PM EST Reads: 1,494
Dec. 2, 2016 02:02 PM EST Reads: 182
Dec. 2, 2016 02:00 PM EST Reads: 4,803
Dec. 2, 2016 01:30 PM EST Reads: 5,686
Dec. 2, 2016 01:30 PM EST Reads: 1,802
Dec. 2, 2016 01:15 PM EST Reads: 2,069
Dec. 2, 2016 01:00 PM EST Reads: 1,381
Dec. 2, 2016 01:00 PM EST Reads: 2,440
Dec. 2, 2016 12:11 PM EST Reads: 221
Dec. 2, 2016 12:00 PM EST Reads: 1,824
Dec. 2, 2016 12:00 PM EST Reads: 171
Dec. 2, 2016 11:45 AM EST Reads: 1,455
Dec. 2, 2016 11:30 AM EST Reads: 1,845
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Dec. 2, 2016 11:30 AM EST Reads: 3,739
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Dec. 2, 2016 11:00 AM EST Reads: 402